Shenzhen Eureka Biotechnology Co., Ltd., a specialist in cell and gene therapy (CGT) based in China, has successfully raised over RMB 300 million (approximately USD 41.7 million) in a Series B+ financing round. The funding was led by Yuexiu Capital, with notable participation from Fortune Capital, Guangdong Technology Financial Group, Tasly Holding, ABC Capital, and returning investor Eight Roads, among others.
The proceeds from this financing will support the advancement of slow virus vector (LVV) large-scale production technology, accelerate the research and development of adeno-associated virus vector (AAV) large-scale production technology, and enhance the overall solution for automated cell drug manufacturing. Additionally, the funding will facilitate the expansion of international markets and operational capabilities.
Established in 2014, Eureka Bio is recognized for its proprietary CellSep series cell processing system and the EuLV lentivirus vector mass production system based on stable cell lines.- Flcube.com
